Methods of treating asthma by administering interleukin-17 receptor
View Patent ↗Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
1. A method for treating asthma, comprising administering to an individual having asthma a composition comprising an effective amount of an Interleukin-17 receptor (IL-17R) protein selected from the group consisting of:
(a) a protein comprising amino acids 28 through 320 of SEQ ID NO:10;
(b) a protein consisting of amino acids 28 through 320 of SEQ ID NO:10; and
(c) a fragment of (b), wherein said fragment binds IL-17;
and a suitable carrier.
2. The method of claim 1 , wherein the composition comprising an Interleukin-17 receptor protein comprises a protein comprising amino acids 28 through 320 of SEQ ID NO:10.
3. The method of claim 1 , wherein the composition comprising an Interleukin-17 receptor protein comprises a fragment of a protein consisting of amino acids 28 through 320 of SEQ ID NO:10, wherein said fragment binds IL-17.
4. The method of claim 1 , wherein the Interleukin-17 receptor protein is a fusion protein.
5. The method of claim 4 , wherein the Interleukin-17 receptor protein is a Fc fusion protein.
6. The method of claim 5 , wherein the Interleukin-17 receptor Fc fusion protein comprises an IgG1 Fc domain.
7. The method of claim 6 , wherein the Interleukin-17 receptor IgG1 Fc fusion protein comprises a human IgG1 Fc domain.
8. The method of claim 7 , wherein the Interleukin-17 receptor human IgG1 Fc fusion protein comprises a human IgG1 Fc domain having the amino acid sequence of SEQ ID NO:4.
9. The method of claim 4 , wherein the Interleukin-17 receptor protein is an oligomeric Fc fusion protein.
10. The method of claim 4 , wherein the Interleukin-17 receptor fusion protein comprises a FLAG® peptide having the amino acid sequence of SEQ ID NO:3.
11. The method of claim 4 , wherein the fusion protein comprises an oligomerizing zipper domain linked to the Interleukin-17 receptor protein.
12. The method of claim 11 , wherein the oligomerizing zipper domain is a leucine zipper domain.
13. The method of claim 11 , wherein the fusion protein is oligomeric, such that the oligomeric fusion protein comprises at least two fusion proteins linked at the oligomerizing zipper domains.
14. The method of claim 13 , wherein the oligomerizing zipper domain is a leucine zipper domain.
15. The method of claim 1 , wherein the Interleukin-17 receptor protein is a non-glycosylated protein.
16. The method of any one of claims 1 , 2 , 3 , and 10 , 14 , wherein the Interleukin-17 receptor protein is administered by bolus injection, continuous infusion and/or sustained release.